More MS news articles for October 2000

Luminex Establishes Database to Analyze Early Biological Indicators of Disease

Proprietary LabMAP(TM) Technology Provides the Foundation for Generating Important Information Concerning the Biochemical Basis of Diseases

Monday October 2, 8:00 am Eastern Time
Press Release
SOURCE: Luminex Corporation

AUSTIN, Texas, Oct. 2 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX - news) today unveiled details of a major project that will enable the detection and treatment of diseases at earlier stages by elucidating certain biochemical changes detectable only in blood.

During the initial phase of this project, Luminex researchers will screen tens of thousands of blood samples to assess the role of approximately 300 components in disease. The components to be tested include those identified by experts in the fields of cancer, multiple sclerosis, trauma, arthritis, diabetes, Alzheimer's and heart disease as being significant biochemical markers. This initial screening is part of an ongoing study that is expected to grow to hundreds of thousands of samples, which will be analyzed for up to 1,000 distinct serum components. The results will be analyzed by using several bioinformatic software methods. The company believes this analysis will identify protein patterns associated with various disease states.

"The potential ramifications of this project on our ability to improve health care are enormous," said Ed Davis, Ph.D., Chairman of the Department of Biostatistics at the University of North Carolina. "From faster and more accurate clinical trials to more precise diagnosis of disease and earlier intervention, the benefits of this project will be realized by doctors and patients alike."

The majority of disease-related processes manifest themselves as biochemical changes in the blood, and this observation has historically formed the basis of diagnostic medicine. Identifying these changes is expected to permit earlier detection and treatment of disease and to provide pharmaceutical researchers with a wealth of new drug targets. The study has been designed to take full advantage of Luminex's proprietary LabMAP technology, where miniaturization allows large-scale proteomic arrays to be analyzed quickly and inexpensively in a small amount of sample.

"LabMAP technology is critical to the development of this database," commented Mark Chandler, Ph.D., Chairman and CEO of Luminex. "This platform is the first to allow so many tests on so little blood. The database has the potential to vastly improve medical diagnostics and should make the drug discovery process quicker, cheaper and more effective. These benefits should begin to be realized early next year."

The company anticipates that the potential uses of the database are varied and far-reaching. The information is expected to provide pharmaceutical and biotechnology companies with important insight regarding abnormal expression or function of proteins. These proteins are the targets of action for 99% of the drugs on the market today. In addition, physicians may be able to access the database to screen patients for thousands of diseases quickly, accurately and cost-effectively. Companies developing multi-analyte diagnostics based on the Luminex platform will be able to incorporate new tests into their products based on the findings of this study.

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The company's LabMAP(TM) system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research. The LabMAP(TM) system is sold worldwide and is already in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or LabMAP(TM) can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this press release that state Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. It is important to note that the company's actual results or performance could differ materially from those projected in such forward-looking statements. Factors that could cause such actual results or performance to differ materially include risks and uncertainties relating to unforeseen difficulties in obtaining blood samples and related medical histories, unforeseen technical difficulties in developing the assays, unforeseen technical difficulties in developing the database or the bioinformatics software that will be used to analyze the database information, market demand for any information that may be developed, protection of any intellectual property that may be developed, the effects of current or future governmental regulation of the company's proposed activities and the effects of competition from other companies seeking to develop similar bioinformatics products. In addition, the factors include the risks discussed under the heading "Factors That May Affect Future Results" in Luminex's Form 10-Q for the quarter ended June 30, 2000 as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this release, and Luminex disclaims any intent or obligation to update or revise such forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which such statements are based.
 

Contacts:

Luminex Corporation                           Noonan/Russo
Communications
(512) 219-8020                                   (212) 696-4455
Mark Chandler, Ph.D.                          Joy Bessenger (Investors)
Chairman and CEO                              Shirley Johnson (Media)

SOURCE: Luminex Corporation